Literature DB >> 8244498

Perspectives in the management of central nervous system tumours.

B M Ansari1.   

Abstract

A general review and update in the management of CNS tumours using medulloblastoma as the main model is given in this article. Special emphasis has been placed on the benefits of combined modality treatment for brain tumours. The pathogenesis and management of these tumours is discussed and recommendations made for treatment in developing countries.

Entities:  

Mesh：

Year:  1993        PMID： 8244498     DOI： 10.1007/bf02822182

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  6 in total

Review 1.  Pediatric brain tumors.

Authors:  R E Warnick; M S Edwards
Journal:  Curr Probl Pediatr       Date:  1991-04

2.  Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I).

Authors:  D M Tait; H Thornton-Jones; H J Bloom; J Lemerle; P Morris-Jones
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

3.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

4.  An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas.

Authors:  C H Chang; E M Housepian; C Herbert
Journal:  Radiology       Date:  1969-12       Impact factor: 11.105

5.  Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts.

Authors:  S H Bigner; H S Friedman; B Vogelstein; W J Oakes; D D Bigner
Journal:  Cancer Res       Date:  1990-04-15       Impact factor: 12.701

6.  Trends in survival for childhood cancer in Britain diagnosed 1971-85.

Authors:  C A Stiller; K J Bunch
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.